# reload+after+2024-01-20 02:44:10.340754
address1§100 Technology Center Drive
address2§Suite 300
city§Stoughton
state§MA
zip§02072
country§United States
phone§781 713 3699
fax§781 828 4697
website§https://www.collegiumpharma.com
industry§Drug Manufacturers—Specialty & Generic
sector§Healthcare
longBusinessSummary§Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
fullTimeEmployees§207
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph.', 'age': 59, 'title': 'Co-Founder & Chairman', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 110000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Joseph J. Ciaffoni', 'age': 52, 'title': 'President, CEO & Director', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 1685780, 'exercisedValue': 516498, 'unexercisedValue': 156150}, {'maxAge': 1, 'name': 'Ms. Colleen  Tupper', 'age': 47, 'title': 'Executive VP & CFO', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 848289, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Shirley R. Kuhlmann', 'age': 39, 'title': 'Executive VP, General Counsel, Chief Administrative Officer & Secretary', 'yearBorn': 1984, 'fiscalYear': 2022, 'totalPay': 842898, 'exercisedValue': 0, 'unexercisedValue': 210365}, {'maxAge': 1, 'name': 'Mr. Scott  Dreyer', 'age': 51, 'title': 'Executive VP & Chief Commercial Officer', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 746577, 'exercisedValue': 0, 'unexercisedValue': 143971}, {'maxAge': 1, 'name': 'Dr. Thomas B. Smith FAAFP, M.D.', 'age': 62, 'title': 'Executive VP & Chief Medical Officer', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 692915, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Christopher Shayne James M.D.', 'title': 'Vice President of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Bart J. Dunn', 'title': 'Executive Vice President of Strategy & Corporate Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Scott  Sudduth', 'title': 'Head of Technical Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§9
boardRisk§4
compensationRisk§3
shareHolderRightsRisk§2
overallRisk§3
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.945
priceToSalesTrailing12Months§1.9269139
currency§USD
dateShortInterest§1702598400
forwardEps§3.2
pegRatio§49.4
exchange§NMS
quoteType§EQUITY
shortName§Collegium Pharmaceutical, Inc.
longName§Collegium Pharmaceutical, Inc.
firstTradeDateEpochUtc§1431005400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§ce084fc3-381a-311e-a750-8eb7c247886f
gmtOffSetMilliseconds§-18000000
targetHighPrice§40.0
targetLowPrice§37.0
targetMeanPrice§37.75
targetMedianPrice§37.0
recommendationMean§2.2
recommendationKey§buy
numberOfAnalystOpinions§4
quickRatio§1.047
earningsGrowth§51.976
grossMargins§0.77969
ebitdaMargins§0.44375
trailingPegRatio§None
